Investments
24Portfolio Exits
8Latest BioVeda Capital News
Feb 8, 2017
BioVeda Capital also joined the round. Your cheat sheet on life, in one weekly email. Get our weekly Game Plan newsletter. Sign Up CXA is among a growing crop of startups trying to build an online marketplace for health services, from insurance to data management. Founded by Chief Executive Officer Rosaline Koo, the daughter of an illegal Chinese immigrant who made his way from Mexico to San Francisco by sea, CXA now has annual revenue of S$10 million ($7 million) and counts 45 Fortune 500 companies among its 500 corporate clients, she said. Saverin will join the board of CXA, which plans to expand to 10 countries across Asia in addition to its current markets of Singapore and Hong Kong. Koo, 55, moved to Singapore before starting CXA in 2013 with S$5 million in savings, after a stint overseeing a 14 country-operation for Mercer Marsh Benefits. She grew up in a Los Angeles ghetto during the Watts riots of the 1960s. Like her father, her mother moved to the U.S. from China, leaving two daughters behind when the Communist Party seized her property. A number of venture capital firms and private equity firms had expressed their interest in funding CXA but B Capital and EDBI were picked for this round because of their focus on health and wellness, Koo said. Before it's here, it's on the Bloomberg Terminal.
BioVeda Capital Investments
24 Investments
BioVeda Capital has made 24 investments. Their latest investment was in CXA Group as part of their Series B on February 2, 2017.

BioVeda Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/7/2017 | Series B | CXA Group | $25M | No | B Capital Group, EDBI, OpenSpace Ventures, Philips, and RGAx | 4 |
12/7/2015 | Series C | ASLAN Pharmaceuticals | $34M | No | 2 | |
4/2/2015 | Convertible Note - V | Jaguar Animal Health | $1M | Yes | Delphi Ventures, and Undisclosed Investors | 1 |
2/10/2015 | Series A | |||||
6/12/2014 | Convertible Note |
Date | 2/7/2017 | 12/7/2015 | 4/2/2015 | 2/10/2015 | 6/12/2014 |
---|---|---|---|---|---|
Round | Series B | Series C | Convertible Note - V | Series A | Convertible Note |
Company | CXA Group | ASLAN Pharmaceuticals | Jaguar Animal Health | ||
Amount | $25M | $34M | $1M | ||
New? | No | No | Yes | ||
Co-Investors | B Capital Group, EDBI, OpenSpace Ventures, Philips, and RGAx | Delphi Ventures, and Undisclosed Investors | |||
Sources | 4 | 2 | 1 |
BioVeda Capital Portfolio Exits
8 Portfolio Exits
BioVeda Capital has 8 portfolio exits. Their latest portfolio exit was Clarus Therapeutics on September 09, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/9/2021 | Reverse Merger | 3 | |||
Date | 9/9/2021 | ||||
---|---|---|---|---|---|
Exit | Reverse Merger | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 3 |
BioVeda Capital Acquisitions
1 Acquisition
BioVeda Capital acquired 1 company. Their latest acquisition was Nexchem on December 08, 2009.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
12/8/2009 | Acq - Fin | 1 |
Date | 12/8/2009 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acq - Fin |
Sources | 1 |
BioVeda Capital Team
4 Team Members
BioVeda Capital has 4 team members, including current General Partner, Juanita Fu.
Name | Work History | Title | Status |
---|---|---|---|
Juanita Fu | General Partner | Current | |
Name | Juanita Fu | |||
---|---|---|---|---|
Work History | ||||
Title | General Partner | |||
Status | Current |
Loading...